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Abstract 
Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT) 
worldwide. The safety and efficacy of reducing hospital stay for MM patients undergoing ASCT have been 
widely explored, and different outpatient models have been proposed. However, there is no agreement on 
the criteria for selecting patients eligible for this strategy as well as the standards for their clinical 
management. On the basis of this rationale, the Italian Group for Stem Cell Transplantation (GITMO) 
endorsed a project to develop guidelines for the management of outpatient ASCT in MM, using evidence-
based knowledge and consensus-formation techniques. An expert panel convened to discuss the currently 
available data on the practice of outpatient ASCT management and formulated recommendations 
according to the supporting evidence. Evidence gaps were filled with consensus-based statements. Three 
main topics were addressed: (1) the identification of criteria for selecting MM patients eligible for 
outpatient ASCT management; (2) the definition of standard procedures for performing outpatient ASCT 
(model, supportive care and monitoring during the aplastic phase); (3) the definition of the standard 
criteria and procedures for re-hospitalization during the aplastic phase at home. Herein, we report the 
summary and the results of the discussion and the consensus. 
Introduction 
Multiple myeloma (MM) remains the leading indication for high-dose chemotherapy and 
autologous stem cell transplantation (ASCT) worldwide
1, 2
 and the International Guidelines 
recommend that ASCT should be offered at some point during the treatment program for a 
medically fit patient.
3, 4
 
High-dose melphalan (HDM) at 200 mg/m2 is the standard conditioning for ASCT5, 6 and, today, the 
treatment should be considered a safe procedure with a very low transplant-related mortality 
(TRM).
7, 8, 9
 The significant increase in the waiting lists generated concerns about the appropriate 
use of health care resources and, over the past years, some studies have investigated the safety, 
efficacy and potential cost advantages of reducing hospital stay for patients undergoing ASCT.
10, 11, 
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
 
The ease of administering HDM, the relatively low extra-hematological toxicity and the short 
period of neutropenia
5, 6
 make MM patients ideal candidates for outpatient ASCT programs. 
Standardization of criteria for the outpatient ASCT policy is a relevant goal of the Italian 
hematology and transplant community and may facilitate comparison of retrospective and 
prospective data. The Italian Group for Stem Cell Transplantation (GITMO) endorsed a panel of 10 
experts in the transplant field (MMa, RML, CG, LC, BB, MO, IL, MMo, GM and AO) to propose a 
consensus for the selection criteria and management of MM patients for ASCT procedure in the 
outpatient setting. 
Methods 
A working group of 10 experts from 7 GITMO centers, with specific expertise in the field of ASCT, 
convened four times to:  
 (a) identify common criteria for selecting MM patients eligible for outpatient ASCT; 
 (b) define standard procedures for the ASCT outpatient including the ASCT outpatient model, 
supportive care and monitoring during the aplastic phase; 
 (c) define standard criteria and procedures for re-hospitalization. 
The panel first met on February 2013 and agreed to adopt a nominal group technique to address the 
above-reported issues. Before each meeting, the moderator (AO) asked experts to propose 
statements for each relevant item. The statements were posted by e-mail and discussed in a round-
robin fashion during the meetings. The discussion was facilitated by a moderator who invited each 
expert to express his or her opinion. Voting could be requested when the panel did not reach a 
consensus. The majority rule was adopted in the case of discordance. 
An expert methodologist (LP) and an experienced researcher in the field of MM (FC) supported the 
research and the final version of the consensus. An expert in the management of infections in 
neutropenic patients (CG) was also involved. 
Systematic review of the literature 
An independent librarian carried out a sensitive search in different electronic databases (MedLine, 
the Cochrane Library (CENTRAL)) to select original research articles on modalities and clinical 
outcomes of outpatient ASCT in MM. A comprehensive list of terms was tested across databases. 
Related articles were explored, and a manual search was also performed from retrieved studies. The 
panel experts were asked to report any article possibly missed. Trial registries (for example, 
clinicaltrials.gov) were searched for non-published studies in progress. Two investigators read all 
abstracts. Selected articles had to fulfill the following inclusion criteria: (1) clinical observational or 
experimental study design, (2) inclusion of at least two patients with ASCT. A full paper was 
obtained from all the eligible studies and evidence tables were generated. 
Quality assessment 
Randomized controlled trials were evaluated through the validated quality scale suggested by Jadad 
et al.
28
 The expert panel agreed to focus on the main issues linked to background questions and 
main operative questions (Table 1). After a detailed evaluation of the main trials in this field 
(Tables 2 and 3), 42 specific questions to be addressed separately by each member of the panel were 
identified (see Supplementary File). For each question, a minimum agreement of 80% was required, 
and disagreements were resolved by discussion. The panel formulated the final statements and the 
key recommendations in a plenary GITMO session (September 2014) (Table 4). The final 
manuscript was updated, reviewed and approved by the panel in July 2015. 
Table 1. Major issues addressed by the expert panel for the outpatient ASCT 
management in MM patientsTable 1. Major issues addressed by the expert 
panel for the outpatient ASCT management in MM patients 
 
Abbreviations: ASCT=autologous stem cell transplantation; MM=multiple myeloma. 
Table 2. Retrospective clinical studies focused on the evaluation of management 
and outcome of outpatient ASCT in MM 
 
 Abbreviations: ASCT=autologous stem cell transplantation; EDM=early discharge model (see Figure 1 for details); HDM=high-dose melphalan; 
HPC=hemopoietic progenitor cell; MIOM=mixed impatient–outpatient model (see Figure 1 for details); MM=multiple myeloma; PCP=primary care 
provider; TIA=transit ischemic attack; TOM=total outpatient model (see Figure 1 for details). 
Table 3. Prospective clinical studies focused on the evaluation of management 
and outcome of outpatient ASCT in MM 
 
 Abbreviations: ASCT=autologous stem cell transplantation; EDM=early discharge model (see Figure 1 for 
details); EDOM=early-discharge outpatient model; HC=home care (see Figure 1 for details); HDM=high-dose 
melphalan; IN=inpatient; MM=multiple myeloma; PEG=PEGylated G-CSF; TOM=total outpatient model (see 
Figure 1 for details). 
Background questions 
What is the standard conditioning for MM patients <66-year-old candidates for outpatient ASCT? 
 
The expert panel agreed to focus on MM patients younger than 66 years, mainly because this 
homogeneous setting makes acceptable the outpatient ASCT management in the context of a standard 
conditioning regimen including HDM at 200 mg/m2 (Table 1). For patients older than 66 years there is no 
full agreement on the intensity of HDM, ranging from 100 to 140 mg/m2.29, 30, 31, 32, 33, 34, 35 As 
recently reviewed, the standard conditioning for younger patients is still HDM at 200 mg/m2, and there is 
not any evidence that the addition of other agents may improve clinical outcomes.5, 6 Elderly patients may 
not be good candidates for outpatient ASCT due to their reduced medical fitness and presence of 
comorbidities.10 
Is the ASCT outpatient model safe as the conventional inpatient ASCT model in MM patients? 
 
Reported early morbidity and early mortality rates (TRM at day +100) after conventional inpatient ASCT in 
younger patients were evaluated. Hematological and extra-hematological toxicities and TRM were 
compared with those reported in studies on outpatient ASCT models in MM. 
 
MM patients who received myeloablative regimens followed by ASCT developed severe hematological 
toxicity and duration of aplasia was strictly associated with the amount of CD34+ cells infused. A dose 
greater than or equal to2 × 106 CD34+ cells/kg body weight is characterized by a rapid neutrophil (PMN) 
recovery in most patients.36 No significant advantage has been reported with a CD34+ cell dose higher 
than 2 × 106 CD34+ cells/kg regarding PMN recovery while a significantly slower platelet recovery has been 
observed when compared with doses higher than 5 × 106 CD34+ cells/kg.36, 37, 38, 39, 40, 41 
 
According to the current literature,42, 43, 44 expert panel agreed to define a graft content of greater than 
or equal to2 × 106 CD34+ cells/kg as the standard minimal dose. Moreover, a higher number of CD34+ cells 
(for example, 3–5 × 106/kg) was considered the ideal to minimize the risk of delayed engraftment. 
 
The following end points for hematological toxicity were selected: (1) days of severe neutropenia; (2) 
requirement of transfusion support; (3) days to PMN and platelet engraftment defined as the second 
consecutive day with PMN >500/mmc and platelet >20 000/mmc, without transfusion support for greater 
than or equal to3 days. 
 
As for extra-hematological toxicity, the following end points were selected: (1) incidence of neutropenic 
fever >38 °C (NF); (2) days of NF; (3) days of IV antibiotics; (4) incidence of documented severe infections; 
(5) incidence of severe (grade 3–4 according to WHO definitions) mucositis; (6) incidence of major 
bleedings. 
 
The expert panel agreed that, besides NF, mucositis represents the most frequent complication, although 
its incidence after HDM was extensively reported in a few reports.20, 22, 26 
 
Recent meta-analyses evaluated early TRM in the main randomized studies in MM, which compared ASCT 
with chemotherapy, and single versus tandem ASCT. TRM was 3%, slightly higher after the second ASCT.45, 
46, 47 In a recent large prospective trial, a TRM between 1 and 3% was reported.48 In a US study, early 
TRM was 2% in the 1995–1999 cohort, 2% in the 2000–2004 cohort and 1% in the 2005–2010 cohort.9 Our 
recent national survey in 522 procedures, performed on an outpatient basis, showed an early TRM of 1%.26 
Similar data were reported by Gertz et al.20 and Helbro et al.22 
Which is the preferred model for ASCT outpatient management in MM patients? 
 
The most representative models of ASCT as an outpatient procedure are summarized in Figures 1 and 2. 
There are only a few data to estimate the real impact of outpatient ASCT procedures in western countries. 
The GITMO survey suggested that this practice was still limited to few centers in Italy. Of the 55 centers 
who filled out the survey questionnaire, only 6 had implemented an outpatient ASCT program, which 
overall included 536 procedures out of a total of 1036 ASCT performed between 1998 and 2012. A single-
center survey from Mayo Clinics20 suggested that 39% of 716 MM patients completed the transplant 
procedure as outpatients. Another retrospective series was reported by Holbro et al.,22 who performed 90 
outpatient ASCT with very low TRM though 68% of patients required a hospital stay longer than 7 days. 
Most representative clinical trials of ASCT in MM as an outpatient procedure are summarized in Tables 2 
and 3. 
 
 
Figure 1. Autologous stem cell transplantation for multiple myeloma through an early-discharge 
outpatient model. In-hospital admission for conditioning and HPC infusion with discharge on day one post-
infusion. Homestay during the aplastic phase with a caregiver (about 10 days) during which twice a week 
ambulatory visits are scheduled to deliver supportive care if required. HPC=hemopoietic progenitor cell. 
  
 
Figure 2. Autologous stem cell transplantation for multiple myeloma through a total, delayed 
admission, mixed inpatient-outpatient and home-care outpatient model. (a) HDC and HPC infusion are 
performed as outpatients. After HPC infusion, patients are followed daily on the outpatient service where 
they receive supportive care. (b) Outpatient clinic for CVC insertion, HDC administration and HSC infusion. 
Re-admission is scheduled on day 5. (c) CVC insertion, fluid infusion, HDC, as well as supportive care 
during the aplastic phase are carried out on the outpatient service. Patients are admitted for HPC infusion. (d) 
In-hospital admission for conditioning and HPC infusion with discharge on day 1 post infusion. The program 
provided clinical examination performed twice daily (in the morning and the afternoon), daily physician 
oversight of all evaluations, daily registered-nurse evaluations in the patients’ home. CVC=central venous 
catheter; HDC=high-dose chemotherapy; HPC=hemopoietic progenitor cell. 
 
The panel agreed that differences in ASCT outpatient models and their clinical outcomes in MM 
might heavily rely on local conditions. However, the panel agreed to recommend the most 
frequently implemented model reported in the GITMO survey, which is the ‘early-discharge 
outpatient model’ (EDOM) that allowed a very low re-admission rate26 (Figure 1). Two additional 
issues that influence outpatient ASCT models are the cost-effectiveness and quality of life. Various 
issues must be considered in economics studies, including medical and non-medical direct costs, 
indirect costs, pre-transplant and post-transplant costs. 
A randomized study compared outpatient ASCT with standard inpatient ASCT in 131 patients with 
non-leukemic malignant diseases and showed that the early-discharge model allowed discharge on 
day 0, home stay with a caregiver and outpatient follow-up with, however, a re-admission rate of 
86%.
21
 In this study, HDM was used as conditioning in only 30% of the patients, and the study 
population was extremely heterogeneous. 
The panel agreed that a cost analysis in this setting required prospective studies. Last, there are not 
prospective studies comparing the quality of life (QOL) in MM patients treated with outpatient 
ASCT models. Therefore, the panel agreed that strong recommendations in this setting cannot be 
established. 
 
Operative questions 
How to select MM patients for outpatient ASCT 
General recommendations 
The expert panel agreed that some specific conditions led to define different inclusion/exclusion 
criteria from those currently accepted for conventional inpatient ASCT. Moreover, very few data on 
the outpatient ASCT management of MM patients with impaired renal function or other 
comorbidities are reported.49, 50 
 
The expert panel selected a list of major criteria to enroll patients in an outpatient ASCT program. 
A set of specific questions was answered by each panel members and the results with the final list 
of inclusion/exclusion criteria are reported in the Supplementary File. The panel agreed that 
advanced age (greater than or equal to65 years), poor performance status or presence of relevant 
comorbidities were exclusion criteria.29 The risk of infections should also be carefully evaluated. 
Local epidemiology, infectious history and colonization status by MDR pathogens require a proper 
risk assessment for post-transplant infections. 
Pre-transplant infections 
A history of any severe infection before transplant and the persistence of any microbiological or 
clinical findings that indicate an incomplete resolution of an infection should be considered a 
contraindication to outpatient ASCT. Though completely resolved, a history of severe infections by 
Gram-negative MDR pathogens during the prior 3 months is a contraindication to outpatient ASCT. 
Pre-transplant infectious screening 
Chest X-ray (or CT scan in selected cases) and additional tests, as clinically indicated, should be 
performed before transplant. In patients without documented colonization by Gram-negative MDR 
pathogens, a rectal swab culture should be performed before transplant. When EDOM is planned, 
colonization monitoring should be started before discharge if a Gram-negative MDR pathogen 
infection (or colonization) is documented on the hospital ward. Colonization screening should focus 
on the search of extended spectrum beta-lactamases producer and carbapenem-resistant 
enterobacteria, and of other Gram-negative MDR pathogens (that is, Pseudomonas aeruginosa, 
Acinetobacter spp, Stenotrophomonas maltophilia). Colonization by carbapenem-resistant and 
Gram-negative MDR pathogens is a contraindication to outpatient ASCT given the crucial role 
played by timely MDR-targeted empiric antibiotic therapy in carriers of MDR bacterial 
infections.51, 52 Colonization by extended spectrum beta-lactamases producing Enterobacteriaceae 
do not represent an absolute contraindication, but should be taken into account if empiric 
antibacterial therapy is required during NF (see below). 
Inclusion criteria 
The expert panel recommended the following inclusion criteria: (1) age between 18 and 65 years; 
(2) normal cardiac and lung function as usually performed before a conventional ASCT; (3) absence 
of other relevant organ dysfunctions. Liver impairment, defined as total bilirubin >3 mg/dL, or renal 
impairment, defined as a creatinine clearance <60 ml/min; (4) absence of advanced disease (for 
example, <PR); (5) absence of Gram-negative MDR pathogens colonization or infection during the 
prior 3 months from ASCT. Any severe infection not completely microbiologically or clinically 
resolved is considered a contraindication to outpatient ASCT; (6) place of stay within 1 h drive from 
the hospital; (7) availability of a suitable caregiver 24 h/24 h; (7) a dedicated phone line 24 h/24 h at 
each transplant center to allow patients or their caregivers to contact an expert physician on the 
transplant team; (8) informed consent including a detailed SOP for the caregiver and the outpatient 
management. 
Which supportive therapy for outpatient ASCT? 
Supportive care 
Supportive care should not differ from that recommended for conventional ASCT. It should include 
hydration, management of emesis and metabolic disorders, analgesic therapy and transfusion of 
blood products. All these treatments can routinely be performed in outpatient rooms except for 
severe medical conditions requiring hospitalization (see below). Patients with severe mucositis 
(>grade 2 WHO), unable to drink and requiring continuous treatment with major analgesic drugs 
should rapidly be re-admitted. 
 
The expert panel agreed that supportive therapies may vary in the light of the different outpatient 
ASCT models. Two outpatient ASCT models are employed in the GITMO network: the EDOM and 
delayed admission model (DAM).53 In the EDOM model,10, 23, 26 the most commonly used in 
Italy, patients and caregivers should carefully trained on home behavior and a detailed information 
sheet on the management of mild/moderate mucositis, fever or mucosal bleeding should be 
provided for the general practitioner. In the delayed admission model, discharge is scheduled on day 
1 and re-admission on day 5 post-HSC infusion. The results of this approach, however, do not 
strongly support that the delayed admission model may significantly reduce hospital stay and its 
costs when compared with the other model. 
Antimicrobial prophylaxis 
The expert panel agreed that antimicrobial prophylaxis for outpatient ASCT should not differ from 
that recommended for conventional inpatient ASCT.54, 55, 56, 57, 58 Patients should receive 
antibacterial prophylaxis with ciprofloxacin 500 mg twice daily or levofloxacin 500 mg once a day 
from day 0 until stable neutrophil engraftment. A recent study suggests that Levofloxacin 
prophylaxis is associated with decreased risk of bloodstream infection and fever in patients with 
myeloma undergoing ASCT.59 
 
Primary antifungal prophylaxis is not recommended in the ASCT setting.60, 61 However, in the 
case of symptomatic mucositis, oral fluconazole at 200–400 mg/day should be started until 
complete hematological recovery. Even though the full resolution may have occurred, secondary 
antifungal prophylaxis in patients with previous invasive fungal infections is recommended. 
Antiviral prophylaxis from the day −2 until neutrophil engraftment for up to 3 months post 
transplantation or longer at the discretion of the attending physician is recommended. Pneumocystis 
jiroveci prophylaxis is recommended after engraftment and for 3 months post transplant or until a 
satisfactory immunological recovery (CD4+ lymphocytes cells >200/mmc). 
Infection monitoring 
After discharge, the first follow-up visit should be recommended at day +5 and then scheduled 
twice weekly until sustained hematological recovery. Patients and caregivers and family members 
should be properly trained on careful monitoring of fever and other infectious signs/symptoms. 
Surveillance blood cultures in the absence of fever or other infection signs are not required 
regardless of the presence of a central venous catheter. Finally, surveillance for fungal infections 
with biomarkers (that is, plasma galactomannan, beta-d-glucan, fungal PCR) is not required. 
Management of neutropenic fever 
In the event of fever (body temperature >38 °C in two measurements or >38.3 °C as a single 
measurement) during neutropenia, patients should be evaluated within 1–2 h by an expert 
hematologist on call who will decide on the need for hospitalization and the choice of the 
antimicrobial therapy. The expert panel strongly suggests a 24-h active phone line with the 
hematologist on call in the BMT unit. According to the local policy and based on clinical 
conditions, the clinical examination may be performed either at home, by the general practitioner or 
in an emergency department, in case of worrying symptoms and/or a low MASC score; in both 
cases, the general practitioner will be able to give an immediate feedback to the hematologist on 
call and (if needed) to start an oral antibiotic treatment. The expert panel recommends that a 
detailed standard operative procedure in the case of NF should be available contextually at the time 
of the informed consensus (a dedicated form must be prepared for the outpatient ASCT procedure), 
not only for the patient but also for the caregiver and the general practitioner. The evaluation of the 
febrile episode should include a physical exam, at least, two blood cultures and imaging when 
clinically indicated. 
Which re-admission criteria and how to manage ASCT outpatients with significant 
complications? 
Re-admission criteria should include: (a) severe mucositis (with/without fever) unresponsive to 
outpatient management; (b) fever with grade greater than or equal to2 mucositis; (c) fever >38.3 °C 
should be evaluated within 1–2  h from onset by an expert hematologist (at least by phone, see 
paragraph ‘Management of NF’). Overall, in patients with a–b–c blood pressure, O2 saturation and 
vital signs should carefully be monitored. After at least 6  h monitoring, hemodynamically stable 
patients without relevant clinical problems may be followed as outpatients. 
 
The expert panel agreed on the potential usefulness of the MASCC score,62 although this index has 
not been validated in the ASCT setting. An MASCC score as low as 21 or lower (high-risk patients) 
was considered a criterion for rapid re-admission through a score higher than 21 was not considered 
a sufficient criteria per se to define patient at low risk and delay re-admission. In case of NF the 
panel agreed on the following re-admission criteria: 
 
 Hemodynamic instability (for example, tachycardia and low blood pressure), impaired 
respiratory function (increased respiratory frequency and low oximetry on room air), 
oliguria, altered mental status and other signs of clinical instability. 
 Grade >2 oral mucositis and diarrhea. 
 Colonization by extended spectrum beta-lactamases producing Enterobacteriaceae 
(colonization by other MDR pathogens). 
 Fever persisting after 2 days of broad spectrum antibacterial therapy. 
 Low compliance of the patient. 
 
The use of empiric antibacterial therapy should follow guidelines/recommendations for patients 
with hematologic malignancies and NF. Empiric broad-spectrum antibacterial therapy should be 
initiated within 1  h from clinical evaluation and after blood cultures have been obtained, and fever 
workup has been completed. IV antibiotics should be preferred and chosen in the light of clinical 
and laboratory findings. Outpatient oral antibiotic therapy (that is, amoxicillin-clavulanate) in low-
risk patients may be considered. 
How to optimize the performance of ASCT outpatients? 
 
The expert panel also addressed three potentially relevant issues which may be critical to improving 
the performance of the outpatients ASCT model: 
 
 Re-hospitalization; 
 NF incidence; 
 QOL. 
 
Re-hospitalization for outpatients is most commonly due to severe oral mucositis (grade 3–4 WHO) 
which requires TPN and narcotic analgesics; NF unresponsive to oral antibiotics which impairs PS 
or determines hemodynamic instability; psychological distress or loss of caregiver support. 
 
Decreased incidence of mucositis in patients transplanted as outpatients is of pivotal importance 
given that mucosal damage increases the risk of many complications that may easily cause re-
admission. Palifermin administered pre- and post-HDM was studied in a randomized fashion with 
no beneficial effect on mucositis incidence and on fever.63 Other studies, however, found a positive 
impact of palifermin on infection rate after BEAM-like conditionings or after TBI.64, 65, 66 
Furthermore, some studies suggested that, though palifermin was not effective in reducing overall 
infection rate (mostly central venous catheter related), its use may reduce ‘severe’ infections such as 
those due to Gram-negative pathogens or accompanied by focal pneumonia.66, 67 
 
In many centers, G-CSF administration is not routinely performed when the source of 
hematopoietic cells is mobilized peripheral blood, and the dose of CD34+ cells infused is largely 
above the threshold required for a proper engraftment. When a CD34+ cell dose >5 × 106/kg is 
employed, neutropenia is unlikely to be further shortened by the administration of post-transplant 
G-CSF. Filgrastim and lenograstim are the standard G-CSF molecules used for enhancing 
neutrophil recovery after ASCT. Very few data on the use of biosimilar G-CSFs have been reported 
so far68, 69 though they have successfully been used for HSC mobilization.69 PEGylated G-CSF 
was also used70, 71 and, in the GITMO survey, many patients on outpatient ASCT programs were 
given PEG-G-CSF.26 
 
The issue about the global economics involved in the outpatient ASCT procedure is still debated. 
However, several experiences suggest that this approach could induce a significant sparing of the 
direct costs, due to the reduced number of hospitalization in intensive care unit.23, 24 
 
Conclusions 
Notwithstanding its appeal, outpatient ASCT in MM has not yet been established as a routine 
procedure, and many transplant centers are reluctant to adopt this approach. However, the extensive 
use of some outpatient ASCT models in MM may contribute to making ASCT more competitive 
especially when compared with some expensive new drugs. Among the different approaches, the 
mixed inpatient/outpatient model was shown to be highly feasible with a very low re-hospitalization 
rate and without increased TRM. One of the reasons for its low implementation may be the lack of 
specific reference recommendations/guidelines. The present consensus may represent a valid tool to 
widen this policy to both Italian and European transplant centers. 
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